|
EMA Urges Quick Communication on Drugmaker GMP Failures
The European Medicines Agency (EMA) is stressing the need for timely, coordinated communications between EU member states when one state learns of a drugmaker’s noncompliance with good manufacturing practices (GMPs) from a non-EU country’s regulator or from an international organization, such as the World Health Organization.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives